First oncolytic virus approved for melanoma immunotherapy

References

• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658–70; PMID:22781695; http://dx.doi.org/10.1038/nbt.2287
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015; 14:642–62; PMID:26323545; http://dx.doi.org/10.1038/nrd4663
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L et al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2014; 3:e28694; PMID:25097804; http://dx.doi.org/10.4161/onci.28694
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2013; 2:e24612; PMID:23894720; http://dx.doi.org/10.4161/onci.24612
   PubMed Web of Science ®Google Scholar
• Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10:292–303; PMID:12595888; http://dx.doi.org/10.1038/sj.gt.3301885
   PubMed Web of Science ®Google Scholar
• Goins WF, Huang S, Cohen JB, Glorioso JC. Engineering HSV-1 vectors for gene therapy. Methods Mol Biol 2014; 1144:63–79; PMID:24671677; http://dx.doi.org/10.1007/978-1-4939-0428-0_5
   PubMedGoogle Scholar
• Cassady KA, Gross M, Roizman B. The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. J Virol 1998; 72:8620–6; PMID:9765401
   PubMed Web of Science ®Google Scholar
• Cassady KA, Gross M, Roizman B. The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J Virol 1998; 72:7005–11; PMID:9696792
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; PMID:24073369; http://dx.doi.org/10.4161/onci.24850
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:25083328; http://dx.doi.org/10.4161/onci.29030
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51–72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
   PubMed Web of Science ®Google Scholar
• Ranki T, Joensuu T, Jager E, Karbach J, Wahle C, Kairemo K, Alanko T, Partanen K, Turkki R, Linder N et al. Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8 T-cell response, prominent infiltration of CD8 lymphocytes and Th1 type polarization. Oncoimmunology 2014; 3:e958937; PMID:25941579; http://dx.doi.org/10.4161/21624011.2014.958937
   PubMedGoogle Scholar
• Spel L, Boelens JJ, Nierkens S, Boes M. Antitumor immune responses mediated by dendritic cells: how signals derived from dying cancer cells drive antigen cross-presentation. Oncoimmunology 2013; 2:e26403; PMID:24482744; http://dx.doi.org/10.4161/onci.26403
   PubMedGoogle Scholar
• De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006; 147:1–11; PMID:16284630; http://dx.doi.org/10.1038/sj.bjp.0706446
   PubMed Web of Science ®Google Scholar
• Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc 2011; 86:1009–26; PMID:21964179; http://dx.doi.org/10.4065/mcp.2011.0309
   PubMed Web of Science ®Google Scholar
• Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12:6737–47; PMID:17121894; http://dx.doi.org/10.1158/1078-0432.CCR-06-0759
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27:5763–71; PMID:19884534; http://dx.doi.org/10.1200/JCO.2009.24.3675
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17:718–30; PMID:19915919; http://dx.doi.org/10.1245/s10434-009-0809-6
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010; 6:941–9; PMID:20528232; http://dx.doi.org/10.2217/fon.10.66
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33:2780–8; PMID:26014293; http://dx.doi.org/10.1200/JCO.2014.58.3377
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Lugli E. Cancer immunotherapy turns viral. Oncoimmunology 2013; 2:e24802; PMID:23734338; http://dx.doi.org/10.4161/onci.24802
   Google Scholar
• Dharmadhikari N, Mehnert JM, Kaufman HL. Oncolytic virus immunotherapy for melanoma. Curr Treat Options Oncol 2015; 16:326; PMID:25777572; http://dx.doi.org/10.1007/s11864-014-0326-0
   PubMed Web of Science ®Google Scholar
• Dolgin E. Oncolytic viruses get a boost with first FDA-approval recommendation. Nat Rev Drug Discov 2015; 14:369–71; PMID:26027526; http://dx.doi.org/10.1038/nrd4643
   PubMed Web of Science ®Google Scholar
• Killock D. Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma. Nat Rev Clin Oncol 2015; 12:438; PMID:26077044; http://dx.doi.org/10.1038/nrclinonc.2015.106
   PubMed Web of Science ®Google Scholar
• Liang M. Clinical development of oncolytic viruses in China. Curr Pharm Biotechnol 2012; 13:1852–7; PMID:21740357; http://dx.doi.org/10.2174/138920112800958760
   PubMed Web of Science ®Google Scholar
• Gujar SA, Clements D, Lee PW. Two is better than one: complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. Oncoimmunology 2014; 3:e27622; PMID:24804161; http://dx.doi.org/10.4161/onci.27622
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74–88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
   PubMed Web of Science ®Google Scholar
• Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 2014; 3:e28518; PMID:25071979; http://dx.doi.org/10.4161/onci.28518
   PubMed Web of Science ®Google Scholar
• Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: radioimmunotherapy for oncological indications. Oncoimmunology 2014; 3:e954929; PMID:25941606; http://dx.doi.org/10.4161/21624011.2014.954929
   Google Scholar
• Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P et al. Classification of current anticancer immunotherapies. Oncotarget 2014; 5:12472–508; PMID:25537519; http://dx.doi.org/10.18632/oncotarget.2998
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; http://dx.doi.org/10.4161/onci.22789
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; http://dx.doi.org/10.4161/onci.27297
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2015; 22:58–73; PMID:25236395; http://dx.doi.org/10.1038/cdd.2014.137
   PubMed Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3:e955691; PMID:25941621; http://dx.doi.org/10.4161/21624011.2014.955691
   PubMed Web of Science ®Google Scholar
• Workenhe ST, Mossman KL. Rewiring cancer cell death to enhance oncolytic viro-immunotherapy. Oncoimmunology 2013; 2:e27138; PMID:24498567; http://dx.doi.org/10.4161/onci.27138
   PubMed Web of Science ®Google Scholar
• Jiang H, Fueyo J. Healing after death: antitumor immunity induced by oncolytic adenoviral therapy. Oncoimmunology 2014; 3:e947872; PMID:25954598; http://dx.doi.org/10.4161/21624011.2014.947872
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol 2015; 15:405–14; PMID:26027717; http://dx.doi.org/10.1038/nri3845
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 2015; 28:690–714; PMID:26678337; http://dx.doi.org/10.1016/j.ccell.2015.10.012
   Web of Science ®Google Scholar